News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to…
Jon OggEach weekend we review the many analyst calls we track during the week. Some turn out to be very insightful and some turn out to be not so great. For better…
US equities markets opened lower this morning following surprisingly weak manufacturing reports from Europe and China. Fitch Ratings’ downgrade of Greek debt to ‘CCC’ could not have been a surprise, but the…
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Advanced Semiconductor Engineering, Inc. (NYSE: ASX) Cut to Neutral at BofA/ML. Apple Inc.…
US markets opened higher this morning and traded higher for most of the day. The DJIA briefly rose above 13,000 for the first time in nearly 3 years. But in the early…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning: ABB Limited (NYSE: ABB) Cut to Equal Weight at Morgan Stanley.…
US stocks opened mixed this morning, with the Nasdaq opening lower than both the DJIA and the S&P 500. The Nasdaq briefly crossed into positive territory this morning, but has traded lower…
At about noon ET today, two of the three major equity indexes remain solidly positive, with the DJIA up nearly 20 points at about 12,924 and the S&P 500 up less than…
Paul Ausick Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug experienced close to a total failure in an arm of a late-stage…
Two of the three major US equities indexes opened higher this morning with the Nasdaq composite being the laggard. The gains are modest due to any news from Europe on the Greek…
Gilead Sciences Inc. (NASDAQ: GILD) is being crushed after a disappointing result in its Hepatitis C treatment after reporting that a majority of hepatitis C genotype-1 patients who had a previous null…
Jon C. Ogg Shortly after Gilead Sciences Inc. (NASDAQ: GILD) announced its $11 billion acquisition of Pharmasett, the company also reported some very promising results on a hepatitis C drug that came in the acquisition.…
Paul Ausick All three major US stock indexes opened lower this morning and the day was mostly a gentle slide for the rest of the trading session. The failed Greek debt deal weighed on…
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Friday morning. Altera Corporation (NASDAQ: ALTR) Cut to Underperform as Bear of the…
Major indexes reacted positively to this morning’s non-farm payrolls report and the drop in the US unemployment rate from 8.5% to 8.3%. Expectations for the unemployment rate had been no better than…